Faron Net Income vs Depreciation And Amortization Analysis

FARN Stock   172.50  2.50  1.47%   
Faron Pharmaceuticals financial indicator trend analysis is much more than just examining Faron Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Faron Pharmaceuticals is a good investment. Please check the relationship between Faron Pharmaceuticals Net Income and its Depreciation And Amortization accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Net Income vs Depreciation And Amortization

Net Income vs Depreciation And Amortization Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Faron Pharmaceuticals Net Income account and Depreciation And Amortization. At this time, the significance of the direction appears to have strong contrarian relationship.
Net IncomeDepreciation And AmortizationDiversified AwayNet IncomeDepreciation And AmortizationDiversified Away100%
The correlation between Faron Pharmaceuticals' Net Income and Depreciation And Amortization is -0.65. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Depreciation And Amortization in the same time period over historical financial statements of Faron Pharmaceuticals Oy, assuming nothing else is changed. The correlation between historical values of Faron Pharmaceuticals' Net Income and Depreciation And Amortization is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Faron Pharmaceuticals Oy are associated (or correlated) with its Depreciation And Amortization. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation And Amortization has no effect on the direction of Net Income i.e., Faron Pharmaceuticals' Net Income and Depreciation And Amortization go up and down completely randomly.

Correlation Coefficient

-0.65
Relationship DirectionNegative 
Relationship StrengthWeak

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Faron Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Faron Pharmaceuticals Oy operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.
Most indicators from Faron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Faron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Faron Pharmaceuticals Oy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Selling General Administrative is likely to gain to about 9.1 M in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.
 2021 2022 2023 2024 (projected)
Interest Expense235K1.4M2.2M2.3M
Depreciation And Amortization306K300K197K185.2K

Faron Pharmaceuticals fundamental ratios Correlations

0.210.70.490.270.38-0.59-0.420.420.250.240.670.680.40.240.790.360.41.0-0.04-0.430.750.34-0.440.980.98
0.210.260.86-0.850.680.65-0.850.880.550.990.160.240.740.990.190.860.950.190.880.140.38-0.810.670.190.19
0.70.260.61-0.060.7-0.26-0.620.460.460.310.820.550.60.330.890.450.510.690.05-0.590.77-0.01-0.370.610.61
0.490.860.61-0.680.860.34-0.950.980.580.850.560.450.80.860.550.910.970.480.74-0.30.67-0.580.380.440.44
0.27-0.85-0.06-0.68-0.6-0.920.71-0.71-0.46-0.830.020.07-0.6-0.840.09-0.72-0.770.29-0.87-0.18-0.10.98-0.810.30.3
0.380.680.70.86-0.60.3-0.920.790.350.680.60.320.870.710.620.780.820.370.47-0.40.54-0.540.160.30.3
-0.590.65-0.260.34-0.920.3-0.410.40.290.63-0.32-0.350.340.63-0.380.420.49-0.610.740.43-0.26-0.950.87-0.61-0.61
-0.42-0.85-0.62-0.950.71-0.92-0.41-0.9-0.46-0.85-0.48-0.4-0.92-0.87-0.58-0.87-0.94-0.41-0.680.21-0.640.64-0.32-0.35-0.35
0.420.880.460.98-0.710.790.4-0.90.530.860.450.390.740.860.420.930.960.40.79-0.250.6-0.620.470.380.38
0.250.550.460.58-0.460.350.29-0.460.530.570.470.160.40.560.340.450.590.210.45-0.180.33-0.440.280.210.21
0.240.990.310.85-0.830.680.63-0.850.860.570.190.250.761.00.230.860.950.220.850.140.41-0.80.620.220.22
0.670.160.820.560.020.6-0.32-0.480.450.470.190.190.470.20.820.380.410.66-0.05-0.750.550.07-0.350.580.58
0.680.240.550.450.070.32-0.35-0.40.390.160.250.190.320.260.460.410.380.680.16-0.220.790.16-0.230.70.7
0.40.740.60.8-0.60.870.34-0.920.740.40.760.470.320.780.580.740.820.390.51-0.090.56-0.570.20.360.36
0.240.990.330.86-0.840.710.63-0.870.860.561.00.20.260.780.240.870.950.220.840.120.42-0.810.60.220.22
0.790.190.890.550.090.62-0.38-0.580.420.340.230.820.460.580.240.330.430.79-0.07-0.60.680.15-0.460.690.69
0.360.860.450.91-0.720.780.42-0.870.930.450.860.380.410.740.870.330.930.340.71-0.270.6-0.650.390.350.35
0.40.950.510.97-0.770.820.49-0.940.960.590.950.410.380.820.950.430.930.380.81-0.120.58-0.710.490.350.35
1.00.190.690.480.290.37-0.61-0.410.40.210.220.660.680.390.220.790.340.38-0.06-0.430.740.36-0.450.980.98
-0.040.880.050.74-0.870.470.74-0.680.790.450.85-0.050.160.510.84-0.070.710.81-0.060.270.27-0.810.86-0.06-0.06
-0.430.14-0.59-0.3-0.18-0.40.430.21-0.25-0.180.14-0.75-0.22-0.090.12-0.6-0.27-0.12-0.430.27-0.4-0.250.49-0.37-0.37
0.750.380.770.67-0.10.54-0.26-0.640.60.330.410.550.790.560.420.680.60.580.740.27-0.4-0.02-0.250.720.72
0.34-0.81-0.01-0.580.98-0.54-0.950.64-0.62-0.44-0.80.070.16-0.57-0.810.15-0.65-0.710.36-0.81-0.25-0.02-0.780.380.38
-0.440.67-0.370.38-0.810.160.87-0.320.470.280.62-0.35-0.230.20.6-0.460.390.49-0.450.860.49-0.25-0.78-0.43-0.43
0.980.190.610.440.30.3-0.61-0.350.380.210.220.580.70.360.220.690.350.350.98-0.06-0.370.720.38-0.431.0
0.980.190.610.440.30.3-0.61-0.350.380.210.220.580.70.360.220.690.350.350.98-0.06-0.370.720.38-0.431.0
Click cells to compare fundamentals

Faron Pharmaceuticals Account Relationship Matchups

Faron Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets10.2M8.4M13.2M11.3M10.2M10.5M
Short Long Term Debt Total2.8M3.2M3.5M13.3M13.1M13.8M
Other Current Liab2.8M4.1M4.3M3.3M2.4M2.7M
Total Current Liabilities6.1M6.5M7.2M10.5M15.0M15.8M
Total Stockholder Equity1.6M(1.8M)2.9M(11.5M)(15.2M)(14.4M)
Net Debt(4.2M)(883K)(3.3M)6.3M6.2M6.5M
Retained Earnings(80.0M)(96.6M)(116.3M)(143.7M)(172.2M)(163.6M)
Accounts Payable3.0M2.1M2.2M5.1M9.0M9.4M
Non Current Assets Total1.0M996K1.2M1.5M1.4M1.3M
Long Term Debt2.3M2.7M2.9M11.1M9.4M9.9M
Net Receivables1.3M1.3M1.4M905K1.0M981.9K
Common Stock Shares Outstanding39.9K46.8K51.8K60.1K68.8K40.5K
Liabilities And Stockholders Equity10.2M8.4M13.2M11.3M10.2M10.5M
Non Current Liabilities Total2.5M3.7M3.1M12.3M10.4M10.9M
Other Current Assets2.1M3.3M5.2M2.7M2.0M2.5M
Other Stockholder Equity78.8M91.9M(1K)129.4M154.2M161.9M
Total Liab8.6M10.2M10.3M22.7M25.4M26.7M
Total Current Assets9.2M7.4M12.0M9.7M8.9M9.2M
Accumulated Other Comprehensive Income78.9K92.0K116.5K129.5K154.4K162.1K
Intangible Assets529K565K899K1.2M1.1M691.5K
Net Tangible Assets1.1M(2.4M)2.0M(12.6M)(11.4M)(10.8M)
Short Long Term Debt163K122K429K1.9M3.5M3.6M
Cash7.1M4.1M6.9M7.0M6.9M5.4M
Cash And Short Term Investments7.1M4.1M6.9M7.0M6.9M5.4M
Property Plant And Equipment Net399K375K207K327K204K195.6K
Property Plant And Equipment Gross399K375K207K327K225K198.1K
Property Plant Equipment399K375K207K327K376.1K192.0K
Non Currrent Assets Other77K56K53K60K54K51.3K
Net Invested Capital4.0M1.0M6.3M1.5M(2.3M)(2.1M)
Net Working Capital3.1M868K4.8M(741K)(6.1M)(5.8M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Faron Stock Analysis

When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.